These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11547779)

  • 1. High rate of indigenous bronchiolitis and palivuzumab.
    Whitehall JS; Bolisetty S; Whitehall JP; Francis F; Norton R; Patole SK
    J Paediatr Child Health; 2001 Aug; 37(4):416-7. PubMed ID: 11547779
    [No Abstract]   [Full Text] [Related]  

  • 2. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.
    Suresh S; Schilling S; Dakin C; Harris MA
    J Paediatr Child Health; 2003 Nov; 39(8):637. PubMed ID: 14629536
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic disadvantages of palivizumab.
    Smith RA; Boon R
    Arch Dis Child; 2000 Apr; 82(4):336. PubMed ID: 10766708
    [No Abstract]   [Full Text] [Related]  

  • 4. From chimpanzee coryza to palivizumab: changing times for respiratory syncytial virus.
    Ogra PL
    Pediatr Infect Dis J; 2000 Aug; 19(8):774-9; discussion 811-3. PubMed ID: 10959757
    [No Abstract]   [Full Text] [Related]  

  • 5. [Palivizumab and bronchiolitis: need to apply the efficiency in order to join clinical practice to scientific studies].
    González de Dios J; Ochoa Sangrador C
    Med Clin (Barc); 2005 Apr; 124(12):478-9. PubMed ID: 15826590
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in the treatment and prevention of severe viral bronchiolitis.
    Domachowske JB; Rosenberg HF
    Pediatr Ann; 2005 Jan; 34(1):35-41. PubMed ID: 15693214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D; Schonfeld T; Amir J;
    Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for the use of palivizumab in infants and young children with congenital heart disease.
    Nakazawa M; Saji T; Ichida F; Oyama K; Harada K; Kusuda S
    Pediatr Int; 2006 Apr; 48(2):190-3. PubMed ID: 16635185
    [No Abstract]   [Full Text] [Related]  

  • 9. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.
    Resch B; Gusenleitner W; Müller WD; Haas J
    Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):120-2. PubMed ID: 16491302
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
    J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab (synagis): counting "costs" and values.
    Carter BS
    Pediatrics; 2000 Nov; 106(5):1168-9. PubMed ID: 11185071
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of palivizumab in primary practice.
    Perrin KM; Bégué RE
    Pediatrics; 2012 Jan; 129(1):55-61. PubMed ID: 22184649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies recommending palivizumab restriction have serious deficiencies.
    Stewart DL
    J Manag Care Pharm; 2010 Sep; 16(7):509-11; author reply 511-2, discussion 512-4. PubMed ID: 20726681
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of respiratory syncytial virus infection in infants.
    Handforth J; Sharland M; Friedland JS
    BMJ; 2004 May; 328(7447):1026-7. PubMed ID: 15117767
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey.
    Prais D; Danino D; Schonfeld T; Amir J
    Chest; 2005 Oct; 128(4):2765-71. PubMed ID: 16236953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of palivizumab: a medical provider's perspective.
    Helm EA; Cummings GE; Keane V; King JC
    Clin Pediatr (Phila); 2003; 42(9):821-6. PubMed ID: 14686554
    [No Abstract]   [Full Text] [Related]  

  • 19. Timing of bronchiolitis hospitalisations and respiratory syncytial virus immunoprophylaxis in non-metropolitan Western Australia.
    Moore HC; Keil AD; Richmond PC; Lehmann D
    Med J Aust; 2009 Nov; 191(10):574. PubMed ID: 19912095
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost minimisation of RSV prevention with palivizumab.
    Wills S; Simpson JH; Coutts J
    Arch Dis Child; 2006 Aug; 91(8):717. PubMed ID: 16861501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.